$SPRO
Spero Therapeutics Inc

2022 Q1 Form 10-Q Financial Statement

#000095017022010064 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $2.069M $7.300M
YoY Change -71.66% 329.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.31M $8.300M
YoY Change 84.4% 102.93%
% of Gross Profit
Research & Development $16.97M $18.40M
YoY Change -7.79% -9.94%
% of Gross Profit
Depreciation & Amortization $189.0K $159.0K
YoY Change 18.87% -15.87%
% of Gross Profit
Operating Expenses $32.28M $26.70M
YoY Change 20.87% 8.89%
Operating Profit -$30.21M -$19.40M
YoY Change 55.68% -14.98%
Interest Expense -$2.609M $100.0K
YoY Change -2709.0% -58.33%
% of Operating Profit
Other Income/Expense, Net -$2.622M -$20.00K
YoY Change 13010.0% -95.42%
Pretax Income -$32.83M -$19.42M
YoY Change 69.05% -16.51%
Income Tax
% Of Pretax Income
Net Earnings -$32.80M -$19.40M
YoY Change 69.07% -16.74%
Net Earnings / Revenue -1585.31% -265.75%
Basic Earnings Per Share -$1.01
Diluted Earnings Per Share -$1.007M -$660.3K
COMMON SHARES
Basic Shares Outstanding 32.76M
Diluted Shares Outstanding 32.61M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.0M $115.7M
YoY Change 5.42% 30.29%
Cash & Equivalents $72.11M $77.04M
Short-Term Investments $49.86M $38.60M
Other Short-Term Assets $8.747M $5.200M
YoY Change 68.21% 36.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $132.7M $129.5M
YoY Change 2.47% 32.14%
LONG-TERM ASSETS
Property, Plant & Equipment $888.0K $8.400M
YoY Change -89.43% 21.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.929M $5.200M
YoY Change 14.02% 10.64%
Total Long-Term Assets $13.13M $13.90M
YoY Change -5.57% 16.81%
TOTAL ASSETS
Total Short-Term Assets $132.7M $129.5M
Total Long-Term Assets $13.13M $13.90M
Total Assets $145.8M $143.4M
YoY Change 1.69% 30.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.780M $3.800M
YoY Change 25.79% -57.78%
Accrued Expenses $10.43M $13.90M
YoY Change -24.97% 0.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $69.20M $17.80M
YoY Change 288.76% -21.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $14.16M $6.800M
YoY Change 108.21% 44.68%
Total Long-Term Liabilities $14.16M $6.800M
YoY Change 108.21% 44.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.20M $17.80M
Total Long-Term Liabilities $14.16M $6.800M
Total Liabilities $83.36M $24.60M
YoY Change 238.85% -10.55%
SHAREHOLDERS EQUITY
Retained Earnings -$400.3M -$297.1M
YoY Change 34.74%
Common Stock $462.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $62.47M $118.8M
YoY Change
Total Liabilities & Shareholders Equity $145.8M $143.4M
YoY Change 1.69% 30.48%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$32.80M -$19.40M
YoY Change 69.07% -16.74%
Depreciation, Depletion And Amortization $189.0K $159.0K
YoY Change 18.87% -15.87%
Cash From Operating Activities -$28.22M -$15.48M
YoY Change 82.33% -33.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$16.06M $3.000M
YoY Change -635.47% -89.23%
Cash From Investing Activities -$16.06M $3.003M
YoY Change -634.93% -89.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.626M $4.253M
YoY Change -14.74%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.814M 4.309M
YoY Change -11.49% -85.73%
NET CHANGE
Cash From Operating Activities -28.22M -15.48M
Cash From Investing Activities -16.06M 3.003M
Cash From Financing Activities 3.814M 4.309M
Net Change In Cash -40.47M -8.167M
YoY Change 395.57% -123.58%
FREE CASH FLOW
Cash From Operating Activities -$28.22M -$15.48M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
CY2021Q1 spro Interest Expense Related To The Sale Of Future Royalties
InterestExpenseRelatedToTheSaleOfFutureRoyalties
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001701108
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 spro Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38266
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
SPERO THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4590683
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
371000
CY2021Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
361000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8747000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8829000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
132704000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
157872000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
888000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1026000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6309000
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2022Q1 dei City Area Code
CityAreaCode
857
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
242-1600
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
SPRO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32821544
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72111000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112584000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49855000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33818000
CY2022Q1 us-gaap Other Receivables
OtherReceivables
1620000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
2280000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6530000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5929000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5644000
CY2022Q1 us-gaap Assets
Assets
145830000
CY2021Q4 us-gaap Assets
Assets
171072000
CY2022Q1 spro Liability Related To The Sale Of Future Royalties Current
LiabilityRelatedToTheSaleOfFutureRoyaltiesCurrent
50902000
CY2021Q4 spro Liability Related To The Sale Of Future Royalties Current
LiabilityRelatedToTheSaleOfFutureRoyaltiesCurrent
0
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4780000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1101000
CY2022Q1 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9060000
CY2021Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14350000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1369000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1362000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32755559
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32393738
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
33000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
462735000
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2093000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1857000
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
995000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
69199000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18670000
CY2022Q1 spro Liability Related To The Sale Of Future Royalties Non Current
LiabilityRelatedToTheSaleOfFutureRoyaltiesNonCurrent
0
CY2021Q4 spro Liability Related To The Sale Of Future Royalties Non Current
LiabilityRelatedToTheSaleOfFutureRoyaltiesNonCurrent
48414000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5726000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5973000
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
8304000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
8786000
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
802000
CY2022Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
128000
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
138000
CY2022Q1 us-gaap Liabilities
Liabilities
83357000
CY2021Q4 us-gaap Liabilities
Liabilities
82783000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3218152
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3218152
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3218152
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3218152
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
455719000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-400292000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367463000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
62473000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
88289000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
145830000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171072000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18404000
CY2022Q1 spro Grant Revenue
GrantRevenue
1822000
CY2021Q1 spro Grant Revenue
GrantRevenue
7300000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
247000
CY2022Q1 us-gaap Revenues
Revenues
2069000
CY2021Q1 us-gaap Revenues
Revenues
7300000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16971000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15305000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8299000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
32276000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
26703000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30207000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19403000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
72000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
98000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-118000
CY2022Q1 spro Interest Expense Related To The Sale Of Future Royalties
InterestExpenseRelatedToTheSaleOfFutureRoyalties
-2488000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-193000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2622000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-32829000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-19423000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32606715
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29414148
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-32829000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-19423000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-4000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32833000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19419000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-32829000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-19423000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
189000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
159000
CY2022Q1 spro Non Cash Lease Cost
NonCashLeaseCost
221000
CY2021Q1 spro Non Cash Lease Cost
NonCashLeaseCost
199000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3203000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2009000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
19000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-23000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-64000
CY2022Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-193000
CY2022Q1 spro Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
2488000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-660000
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3218000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-31000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-869000
CY2022Q1 spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-1000
CY2021Q1 spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-772000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
285000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3679000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2689000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5290000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
624000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-246000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-10000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-9000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-240000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-195000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28223000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15479000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26970000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2997000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10906000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6000000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16064000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3003000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3626000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4253000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
37000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
188000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
93000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3814000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4309000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40473000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8167000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112584000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
85209000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72111000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
77042000
CY2022Q1 spro Offering And Financing Costs Included In Accounts Payable And Accrued Expenses
OfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
0
CY2021Q1 spro Offering And Financing Costs Included In Accounts Payable And Accrued Expenses
OfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
93000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
88289000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
188000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3626000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3203000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-4000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-32829000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
62473000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
132040000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4123000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2009000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-19423000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
118846000
CY2022Q2 us-gaap Property Plant And Equipment Salvage Value Percentage
PropertyPlantAndEquipmentSalvageValuePercentage
0.75
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-32800000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-19400000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-400300000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses, the valuation of share-based awards and the liability related to the sale of future royalties. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has contemplated the impact of COVID-19 within its financial statements and is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. There may be changes to those estimates in future periods. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.</span></span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of March 31, 2022, and December 31, 2021, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.
CY2022Q1 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2021Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2022Q1 spro Cares Act Eliminated Percentage On Limitation Of Taxable Income
CARESActEliminatedPercentageOnLimitationOfTaxableIncome
0.80
CY2022Q1 spro Cares Act Percentage Of Adjusted Taxable Income Plus Business Interest Income
CARESActPercentageOfAdjustedTaxableIncomePlusBusinessInterestIncome
0.50
CY2022Q1 spro Cares Act Percentage Of Limitation On Adjusted Taxable Income Plus Business Interest Income Under Tax Cut And Jobs Act2017
CARESActPercentageOfLimitationOnAdjustedTaxableIncomePlusBusinessInterestIncomeUnderTaxCutAndJobsAct2017
0.30
CY2022Q1 spro Cares Act Percentage Of Corporate Charitable Deduction Limitation On Taxable Income
CARESActPercentageOfCorporateCharitableDeductionLimitationOnTaxableIncome
0.25
CY2022Q1 spro Cares Act Eligible Cost Recovery Period
CARESActEligibleCostRecoveryPeriod
P15Y
CY2022Q1 spro Cares Act Percentage Of Bonus Depreciation
CARESActPercentageOfBonusDepreciation
1
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25600000
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
600000
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49855000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
33820000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49859000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
33818000
CY2022Q1 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
1000000.0
CY2022Q1 spro Percent Of Aggregate Payment Received
PercentOfAggregatePaymentReceived
2.50
CY2022Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
1000.0
CY2021 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
800000
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
1000000.0
CY2022Q1 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4147000
CY2021Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
6315000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2397000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5884000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1452000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
909000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1064000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1242000
CY2022Q1 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9060000
CY2021Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14350000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24263000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
952604
CY2022Q1 spro Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.96
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.57
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4890716
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.75
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M13D
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.15
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17616
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.72
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
50636
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.80
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5775068
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.63
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M9D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3951000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5775068
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.63
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M9D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3951000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2868263
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.47
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M14D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3684000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8720127
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1143299
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3203000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2009000
CY2022Q1 spro Performance Obligation Allocated Transaction Price
PerformanceObligationAllocatedTransactionPrice
12500000
CY2022Q1 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
50000000.0
CY2022Q1 spro Royalty Issuance Cost
RoyaltyIssuanceCost
2500000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-32829000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-19423000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32829000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19423000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32606715
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29414148
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13305715
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10950140

Files In Submission

Name View Source Status
0000950170-22-010064-index-headers.html Edgar Link pending
0000950170-22-010064-index.html Edgar Link pending
0000950170-22-010064.txt Edgar Link pending
0000950170-22-010064-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-20220331.htm Edgar Link pending
spro-20220331.xsd Edgar Link pending
spro-20220331_cal.xml Edgar Link unprocessable
spro-20220331_def.xml Edgar Link unprocessable
spro-20220331_htm.xml Edgar Link completed
spro-20220331_lab.xml Edgar Link unprocessable
spro-20220331_pre.xml Edgar Link unprocessable
spro-ex31_1.htm Edgar Link pending
spro-ex31_2.htm Edgar Link pending
spro-ex32.htm Edgar Link pending